Scholarly Works - Preprints
Preprint
·
April 24, 2026
BACKGROUND: Patients with prostate cancer who develop androgen pathway modulation resistant (APMR) disease face lethal outcomes despite advances in androgen receptor-pathway inhibitors, chemotherapy, and PSMA-directed radioligands. Antibody-drug conjugates ...
Full text
Link to item
Cite
Preprint
·
November 13, 2025
Prostate cancer (PC) remains the second leading cause of cancer-related mortality in men. The emergence of treatment-emergent neuroendocrine prostate cancer (NEPC) arising from androgen receptor (AR) pathway inhibition poses a significant clinical challeng ...
Full text
Open Access
Link to item
Cite